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Background:  
The role of steroids to mitigate the deleterious effects of the pediatric cardiopulmonary by-pass 
remains a matter of debate therefore we aimed to assess preferences in administering 
corticosteroids and the use of other anti-inflammatory strategies in pediatric cardiac surgery.  
Methods 
A 19-question survey was distributed to consultants in pediatric cardiac anesthesia from 12 
centers across the UK and Ireland.  
Results 
Out of the 37 respondents (37/60, 62%): 24 (65%) use corticosteroids while 13 (35%) do not 
use steroids at all. We found variability within 5 out of the 12 centers (41%). Seven consultants 
(7/24, 29%) administer corticosteroids in every case while 17 in selected cases only (17/24, 
71%). There was variability in the dose of steroid administration. Almost all consultants (23/24, 
96%), administer a single dose at induction and one administers a two-dose regimen (1/24, 4). 
There was variability in corticosteroid indications. Most consultants (24/37, 66%), use 
modified ultrafiltration at conclusion of cardiopulmonary bypass. Fifteen consultants (15/32, 
47%) report the use of aprotinin while only 3 use heparin coated circuits (3/24, 9%).  
Conclusions 
We found wide variability in practice in the administration of corticosteroids for pediatric 
cardiac surgery, both within and between units. While most anesthetists administer 
corticosteroids in at least some cases, there is no consensus on the type of steroid, the dose and 
at which patient groups this should be directed. Modified ultrafiltration is still used by most of 
the centers. Almost half of consultants use aprotinin while heparin coated circuits are 
infrequently used.  
 
 
 
 3 
 
Introduction 
Prophylactic corticosteroids (CS) in pediatric heart surgery using cardiopulmonary 
bypass were introduced in clinical practice almost 60 years ago 1. Despite their long-term use, 
there is ongoing debate regarding their impact on clinical outcomes. Corticosteroids are still 
given prophylactically to dampen the systemic inflammatory response syndrome (SIRS) to the 
extracorporeal circuit. The SIRS results from the contact of the various blood components with 
cardiopulmonary bypass (CPB) circuit, the endothelial cell insult and the associated ischemic 
reperfusion injury 2. In children, these changes are more profound due to the surface of the 
extracorporeal circuit relative to their small circulating blood volume, the more frequent use of 
the deep hypothermic circulatory arrest (DHCA) and more pronounced hemodilution 3. 
However, according to the available evidence, it is unclear if attenuation of the inflammatory 
response ultimately translates into better clinical outcomes 4–7. Is inflammation an adaptive or 
a maladaptive process?  The available randomized controlled trials of steroid versus placebo 
suffer from small sample sizing. This precludes the detection of a significant treatment effect 
on the clinical endpoints 4,6,8–14. The results of an ongoing,  large randomized controlled trial 
(RCT) of CS versus placebo in 1200 neonates are still awaited and hopefully will inform us 
more on this matter15. Notably, two very large registry studies showed no benefit in steroid use 
in pediatric heart surgery and raised concerns regarding infection 16,17.  Furthermore, the long-
term impact of CS in pediatric heart surgery to the developing child is unknown due to the lack 
of long term follow-up studies. A particular concern is the potential deleterious effect on 
neurocognitive development observed in other patient groups 18,19. 
Corticosteroids are also used to protect against relative adrenal insufficiency that could 
potentially occur perioperatively and result in hemodynamic compromise. However, very little 
is known about the physiology of the hypothalamic pituitary adrenal (HPA) axis in children 
undergoing surgery 20,21. How do we define adrenal insufficiency in children undergoing heart 
surgery? Certainly, the use of random time point measurements or various adrenal stimulation 
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tests are likely to be inaccurate in the context of a known dynamic, pulsatile HPA axis activity 
perioperatively 22.  
Another cited justification for corticosteroid administration is their neuro-protective 
effect in complex surgical cases undergoing deep hypothermic circulatory arrest (DHCA). The 
evidence in this area is limited to animal studies and it is conflicting 23,24.  
In view of the existing lack of either evidence or consensus, our survey was designed 
to assess current preferences consultant anesthetists in the UK to administer steroids in 
pediatric heart surgery with cardiopulmonary bypass. As a secondary objective, we also 
surveyed the use other anti-inflammatory strategies including modified ultrafiltration, aprotinin 
and heparin coated circuits.  
 
Material and Methods 
 
A 19-question survey was distributed to the Congenital Cardiac Anesthetic Network (CCAN) 
UK consultant email list. It is estimated that 70-80 doctors practice pediatric cardiac anesthesia 
in the UK and CCAN is a network of these doctors 25. The responses were collected during 
December 2015-November 2016 period and several reiterations were conducted until an 
adequate response from all units was received. Results were collected using the Survey Monkey 
Inc. platform, San Mateo, California, USA and analyzed using Graph Pad Prism version 7.00 
for Windows, La Jolla California USA.  
 
Results  
The survey was sent to 60 consultants from all 12 National Healthcare System units 
across the UK and Ireland performing pediatric heart surgery. We received 37 responses 
(61.7%) with an average of 3 responses per center (ranging from 1 to 5 responses). In 5 out of 
the 12 centers, the practice of administering steroids varied between consultants within that 
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centre (Figure 1 B). Out of the 37 respondents from UK and Ireland: 24 (64.8 %) reported the 
use of CS while 13 (35.1%) do not use CS at all. Seven (7/24, 29.1%) anesthetists administer 
CS in every case while 17 (17/24, 70.8%) in selected cases only (Figure 1 A).  
There were 29 indications cited for steroid use in total, ranging from 1 to 6 indications 
per respondent (n=17). The most common indications for corticosteroid administration was 
surgery in neonates (9, 31%), surgery with use of DHCA (9, 31%), re-do cases (2, 6.9%), the 
Norwood operation (2, 6.9%), high perioperative inotrope requirement (2, 6.9%), complex 
atrial/ventricular septal defects (2, 6.9%), switch operation (1, 3.4%), long CPB time (1, 3.4%) 
and surgery in infants (1, 3.4%)  
The most widely used corticosteroid was dexamethasone used by 17 consultants (17/24, 
70.8%) followed by methylprednisolone used by 4 (4/24, 16.7%) and hydrocortisone used by 
3 consultants (3/24, 12.5%). Almost all consultants (23/24, 95.8 %,) administer a single dose 
of steroid at induction and only one (1/24, 4.2%) administers a two-dose regimen (dose at 
induction and one at 6 hours from the first dose). Dexamethasone doses ranged from 0.5mg/kg 
to 1 mg/kg, methylprednisolone dose ranged from 20mg/kg to 30mg/kg and hydrocortisone 
was administered at a dose of 4mg/kg (Table 1, Supplementary file). If we calculate the 
equivalent anti-inflammatory dose of dexamethasone for the rest of CS administered, there is 
further variation with dexamethasone doses ranging from 0.15 mg/kg up to 5.62 mg/kg (Table 
1, Supplementary file), 26. 
 Most consultants (24/37, 65.9%) use modified ultrafiltration at conclusion of 
cardiopulmonary by-pass. Seven consultants (7/24, 29.25%) use ultrafiltration in children up 
to 6kg, 13 (13/24, 54.2%) in children up to 10 kg and 4 consultants (4/24, 16.7%) in children 
over 10 kg. Out of the 32 respondents: 15 (15/32, 46.9%) consultants use aprotinin and only 3 
(3/24, 9.4%) heparin coated circuits.  
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Comment 
Across the UK and Ireland approximately 4500 pediatric heart operations involving 
cardiopulmonary by-pass are performed every year27. Therefore, understanding the impact of 
steroids on clinical outcomes is an important health issue. In contrast to previous surveys 28,29, 
we have also assessed the preference of steroid administration not only between centers but 
also within centers. In the survey by Checchia et. al 36 responses were returned from each 
center representative 29 and in the survey by Allen et al. 28 only 12 responses were returned in 
total from center representatives. Neither study looked at variation within centers. In our 
survey, we found variation in steroid preferences within 5 centers. This suggests the lack of 
local consensus between consultants and a lack of protocols in certain centers.  
Most consultant anesthetists use CS in pediatric heart surgery (65%) in some form. 
However, we noticed a trend in reduced CS use compared to an international survey by Chechia 
et al.29 from 2005 (97%) and an older UK survey by Allen et al. 28 (80%). Out of the consultants 
that use CS, the majority administer them in selected cases only (71%) compared to 60% and 
58% in the previous surveys of practice 28,29 . This trend towards reserving CS for selected 
cases reflects the ongoing lack of consensus and need for further evidence in the “high risk” 
patient groups.  
We found variability in the indications of CS use. The most common indications for 
steroid use were surgery in neonates (31%) and use of DHCA (31%). Certainly, we know very 
little about the stress response in neonates. The immaturity of their HPA axis means they are 
less likely to cope with the stress of surgery 21. We conducted a recent systematic literature 
review focused on this group and found a limited evidence 12. The use of CS for neuroprotection 
in cases with use DHCA is another unanswered question. The available studies assessing the 
effect on brain protection used piglet cardiopulmonary by-pass models. A study by Langley et 
al. suggested  cerebral protection if methylprednisolone (MP) is given early: 8 to 12 hours pre-
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operatively 23. On the other hand, a study by Schubert et al. 30 showed no benefit for MP 24-
hour pre-treatment. Other indications for CS were aimed at the high-risk procedure groups. 
There are a few studies in this group and the evidence is again conflicting. In a small RCT of 
20 neonates undergoing arterial switch, pre-treatment with MP reduced the expression of 
myocardial and plasma cytokines that translated in lower inotrope requirement and decreased 
myocardial damage6. A large retrospective analysis of 549 neonates who underwent the 
Norwood procedure found intraoperative steroid administration was not associated with 
improvement in outcome. Furthermore, steroid non-recipients had better hospital survival, but 
longer intensive care and hospital stays 31. With regards to inotrope requirements, there is some 
evidence that so-called “rescue” steroids improve hemodynamics and lower inotrope 
requirement 32. In a RCT of 40 neonates by Roberto et al the use of a prophylactic postoperative 
steroid infusion reduced inflammation, improved fluid balance and urine output and allowed a 
faster wean from catecholamines or vasopressin14. Similar to our survey of prophylactic steroid 
administration, a recent survey by Flores et al. 33 found significant variability in the indications 
for corticosteroid administration in patients with severe low cardiac output syndrome.  
We found variation in both the type of steroid used and in terms of the doses 
administered. This is a similar finding to previous surveys of practice 28,29. Almost all 
consultants give one dose at anesthesia induction and only one reported to administer a two-
dose regimen at induction and at 6 hours from the first dose. A few studies on piglet 
cardiopulmonary by-pass models found some benefit of early CS administration on pulmonary 
function 34 and brain protection 23. However, in an RCT of 76 neonates Graham et al. found a 
two-dose regimen (8 hours pre-operative and operative) reduced the pre-operative interleukin-
6 cytokine concentration two-fold compared to the single-dose steroid arm. There was no 
difference in postoperative cytokines or clinical outcomes between the single and two dose 
regimens 35. In contrast to US practice, where steroids are administered in the majority of the 
cases in the prime 36, in our survey we noted that steroids are given most of the time pre-
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operatively, at induction. A three-arm RCT of 45 children evaluated the effect of 
methylprednisolone administration in prime versus intravenously (at induction) during cardiac 
surgery. There was no difference in terms of clinical outcomes between the three groups, 
however, steroids given at induction were superior in terms of anti-inflammatory effect 
compared to the prime route11.  
Modified ultrafiltration use in pediatric heart surgery can remove the excess of water 
and inflammatory mediators during cardiopulmonary by-pass. The impact on postoperative 
course is hemoconcentration, reduced need for transfusions, and improvement of cardiac and 
respiratory function 37. According to previous surveys, its use amongst pediatric heart surgery 
centers ranged from 75-80% 28,29. In the current survey, fewer centers used MUF (e.g. 66%). 
This could be explained by the emergence of low prime volume extracorporeal circuits, 
avoidance of severe hemodilution or efficient use of conventional ultrafiltration that no longer 
justifies the use of MUF and its associated risks 38. Aprotinin is a potent anti-fibrinolytic but 
has also anti-inflammatory properties that could be advantageous in pediatric heart surgery. 
However, its safety profile in both adult and pediatric patients remains a matter of debate 39. 
This is reflected in the current survey where almost half of the consultant reported its use. Very 
few centers use heparin coated circuits.  
There are no studies to date investigating the combined effect of the various anti-
inflammatory modalities.  
The strengths of the current study are the analysis of steroid variation within centers 
and of steroid indications for the various patient groups. The weakness of this study is its 
response rate of only 61.7 %. However, this compares to previous surveys on this topic. 
Another source of bias could be steroid administration by other healthcare professionals 
including surgeons, intensivists or perfusions. However, within UK, the prophylactic, 
perioperative steroid administration is usually governed by the pediatric cardiac anesthetist. 
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The current survey offers the following observations. The use of prophylactic 
corticosteroids in pediatric heart surgery remains a matter of intense debate. We found 
variations in steroid administration both within centers and between centers. Most consultant 
anesthetists surveyed give steroids in selected cases. However, there was heterogeneity in the 
cited indications, dose and type of steroid used. Of those that used steroids, almost all 
administer a single dose of CS preoperatively at induction. These results reflect the lack of 
evidence from placebo controlled randomized trials of CS versus placebo, powered to look at 
the impact on clinical outcomes. In the context of the low mortality and morbidity associated 
with pediatric heart surgery, the obstacle to conducting such research is the recruitment of a 
sufficiently large sample size to detect any effect. This also implies that effect size of 
corticosteroid use is small across a population or may be limited to selected pathologies. This 
survey also highlights the need to investigate the role of steroids in the “vulnerable” patient 
groups such as neonates or complex surgical cases with use of deep hypothermic circulatory 
arrest.  
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Figure Legends 
Figure 1 Corticosteroid preferences (1 A) variation within and between centers (1B) 
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